Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat

Overview of attention for article published in BMC Pulmonary Medicine, May 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective

Article in Vascular Health and Risk Management (October 2022)

The Efficacy of Transitioning Patients With Pulmonary Hypertension From Phosphodiesterase Type 5 Inhibitors To Riociguat: A Systematic Analysis And Retrospective Chart-Review

Preprint in Research Square (July 2021)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Article in Pulmonary Circulation (January 2020)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.